Dual Tim-3 and PD-1 blockade [67, 69] or even combining anti-Tim-3, anti-PD-1, and anti-CTLA-4 [71] shows synergistic anti-tumor effects in several cancer types, more effective than any monotherapy. This evidence concerns the gene HAVCR2 and neoplasm.